Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 07 Oct 2019 Status changed from not yet recruiting to recruiting.
- 06 Aug 2019 Planned initiation date changed from 1 Apr 2019 to 1 Sep 2019.
- 24 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Apr 2019.